Sidley Austin represented OMERS Life Sciences in the transaction, while Latham & Watkins advised Verona Pharma and Sullivan & Cromwell represented Oaktree Capital Management, L.P. Verona...
Verona Pharma’s $650 Million Financing Round
Gilead’s $2 Billion Senior Unsecured Notes Offering
Davis Polk advised Gilead, and Latham & Watkins advised the underwriters. Gilead Sciences, Inc. (Nasdaq: GILD) announced the pricing of senior unsecured notes in an aggregate...
Harps Global’s Acquisition of a Medical Division from Semperit
Schoenherr and Latham & Watkins advised Harps Global on the deal. Harps Global PTE. LTD executed the acquisition of the medical business division (Sempermed) from Austrian...
Cordis’ Acquisition of MedAlliance
Latham & Watkins represented MedAlliance in the transaction. Swiss-based medical technology company MedAlliance announced it has entered into an agreement with Cordis for an acquisition which includes...
Nordic Capital’s Investment Into Equashield
Latham & Watkins LLP represented Nordic Capital in the transaction. Nordic Capital, a leading private equity investor, and Equashield have announced that Nordic Capital has joined Equashield’s...
Goldman Sachs Asset Management’s Acquisition of Controlling Stake in Norgine Europe
Latham & Watkins has advised Norgine Europe B.V. on the deal. Allen & Overy and White & Case have advised Goldman Sachs Asset Management Division. Norgine...
CooperCompanies’ Acquisition of Cook Medical’s Reproductive Health Business
Latham & Watkins represented CooperCompanies in the transaction. CooperCompanies has announced it has signed a binding letter of intent to acquire Cook Medical’s Reproductive Health business, a manufacturer...